406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment

Episode Overview

• Physician and The Drive podcast host Peter Attia, M.D. (who notes 25% of his audience are physicians) interviews Brian Grosberg, M.D., a fellowship-trained headache specialist, neurologist, and director of an academic headache program in Hartford, Connecticut (formerly in New York) who had never been on or listened to a podcast in his life. No financial disclosures, business ties, funding, or sponsors were disclosed, though Grosberg notes his center was the global lead trial site for FDA clearance of the Nerivio armband device, conducted a large outpatient cannabinoid survey, and is conducting an ongoing study on presenteeism in migraine.
• The episode addresses a critical clinical gap: although over 300 headache disorders exist and migraine alone affects 12% of the global population, medical students and neurology residents receive only a few hours of headache education across their training, and only about 50 fellowship-trained headache specialists graduate in the U.S. annually.
• The narrative progresses from how clinicians classify primary headaches without blood or imaging biomarkers into a deep dive on the clinical presentation, pathophysiology, and distinct phases of tension-type headache, migraine, and cluster headache.
• The discussion explores hormonal drivers across the female lifespan (menstruation, pregnancy, and menopause) and modifiable risk factors that cause episodic headaches to transform into chronic, daily pain.
• Finally, Attia and Grosberg evaluate the therapeutic landscape—spanning repurposed blood pressure, antidepressant, and anti-seizure drugs, Botox, targeted CGRP antagonists, triptans, and external neuromodulation devices—while detailing the "red flag" symptoms that indicate life-threatening secondary headaches.

Key Concepts

• Primary vs. Secondary Headache Classification: The International Classification of Headache Disorders outlines over 300 types and causes of headaches. Because there are no blood biomarkers or MRI/CT findings that diagnose primary headaches, diagnosis relies entirely on clinical history and symptom patterns after ruling out secondary structural, infectious, or vascular causes.
• Tension-Type Headache: The most common headache overall, split evenly between men and women. It presents on both sides of the head, face, or neck with mild-to-moderate, non-pulsating pain lasting 30 minutes to a week. Patients have no nausea and may experience light sensitivity or sound sensitivity, never both. Episodic is <15 days per month; chronic is $\ge$15 days per month.
• Migraine Epidemiology & Economic Burden: Migraine is the leading headache reason patients seek medical or ER care, affecting 12% of the population (1 billion worldwide; ~45 million in the U.S.). It disproportionately affects women three times more often than men (18% of women, or nearly 1 in 5). A colleague of Grosberg postulated—as theory rather than proven fact—that women may have evolved hyperexcitable neural networks to sense inclement weather/danger as caregivers or to multitask. Migraine costs the workplace billions of dollars (Attia estimates hundreds of billions) through absenteeism and even more heavily through presenteeism (working at reduced capacity).
• Migraine Diagnostic Criteria & Myths: Diagnosis requires at least 5 lifetime attacks lasting 4 to 72 hours (untreated or unsuccessfully treated) with at least two of four features: (1) one-sided pain (though despite the root word hemicrania meaning half-head, up to 40% experience pain on both sides), (2) pulsating/throbbing quality, (3) moderate-to-severe intensity, and (4) aggravation by or avoidance of routine physical activity—plus nausea/vomiting and/or both light and sound sensitivity. Meeting criteria without all features may be classified as "probable migraine." Episodic migraine is <15 headache days per month; chronic migraine is $\ge$15 days per month (affecting 1%–2% of the population). Status migrainosus is a prolonged attack lasting >3 days (Grosberg's first resident patient had a 6-week migraine).
• The "Sinus Headache" Myth: Grosberg states flatly that "there is no such thing as a sinus headache"—only acute or chronic rhinosinusitis. During migraine or cluster attacks, activation of the parasympathetic nervous system alongside the trigeminal nerve triggers tearing, eye redness, and nasal congestion/rhinorrhea, frequently leading to misdiagnoses of sinus infections or dental problems and unnecessary surgeries.
• The Four Phases of Migraine:
• Phase 1 (Premonitory/Prodromal): Occurs minutes, hours (the median), or days before pain in ~60% to the high-80s% of patients (depending on population- vs. clinic-based studies). Symptoms include yawning, food cravings, tiredness, irritability, light sensitivity, and neck stiffness.
• Phase 2 (Aura): Experienced by only 25% to 33% of migraine patients (67%–75% never have an aura). Caused by cortical spreading depolarization starting in the visual cortex, aura evolves gradually over 5 to 60 minutes with positive and negative phenomena, distinguishing it from a TIA or stroke, which is maximal at onset and typically involves negative visual loss only.
• Phase 3 (Headache & Allodynia): Roughly 2/3 to 70% of patients develop cutaneous allodynia (central sensitization kicking in ~30–60 minutes into an attack), making normal stimuli like a ponytail, brushing hair, tight hats, or glasses feel painful.
• Phase 4 (Postdrome/Post-ictal): A "hangover" phase lasting hours to a couple of days after pain resolves, affecting 60% to the high-80s% of patients.
• Hormonal Influences Across the Female Lifespan: Roughly 2/3 of women with migraine note a menstrual association (diagnosed when occurring in at least 2 of 3 cycles). Pure menstrual migraine occurs solely around menses (<10% of women with migraine), while menstrually related migraine occurs both at menses and other times (~50%). While 1970s research linked this to late luteal estrogen drops, newer studies by Grosberg's mentee show that women with migraine have a uniquely faster rate and degree of estrogen decline in the late luteal phase. While luteal estrogen supplementation and HRT studies exist, Grosberg cautions that predicting responders is difficult—some women improve, some see no change, and some worsen. During pregnancy, migraine without aura improves in ~47% of women in the first trimester and 80%–87% in the second and third trimesters. After completing the menopause transition, ~2/3 of women improve, while 10%–20% continue or worsen.
• Triggers vs. Causes & Chronification Risk Factors: Triggers do not cause headache disorders; they elicit attacks in biologically predisposed brains. For example, the "weekend letdown" triggers migraines via three simultaneous shifts: dropping stress/endorphin levels, sleeping in later, and delaying morning caffeine by 2–3 hours. Risk factors that drive episodic migraine into chronic migraine include baseline attack frequency ($\ge$5 headache days/month or $\ge$1 migraine/week), obesity (BMI 30–35 carries a 2x risk; BMI $\ge$35 carries a 5x risk, with surgical and non-surgical weight loss showing improvement), medication overuse ($\ge$2 days/week of acute meds), stressful life events, sleep disturbances (insomnia, sleep apnea), bidirectional mood disorders (depression/anxiety), other pain disorders, unaddressed nausea, and suboptimally treated acute attacks.
• Cluster Headache Presentation & Periodicity: Nicknamed "suicide headache" due to exquisite pain (patients may take their lives), cluster headache is rare and affects men 3 to 4 times more often than women. It is strictly side-locked (in, around, or behind one eye), peaks rapidly within 5 to 15 minutes, lasts 15 minutes to 3 hours, and occurs from once every other day up to 8 times daily (average 3/day). Episodic cluster headache features cluster periods of weeks to months followed by remission; chronic cluster headache has no breaks. Up to 97% of patients have ipsilateral autonomic signs (droopy eyelid/ptosis, tearing, redness, nasal congestion), and 90% experience severe restlessness/agitation. Attacks show circannual periodicity—peaking in January/February, July/August, and around daylight saving time changes—though Grosberg hedges that locking circadian rhythms with a 50,000 lux light setup is not a certainty to eliminate attacks.
• Preventive Pharmacology & Botox: Although ~40% of migraine patients are eligible for preventive therapy, only 16%–17% receive it. Conventional repurposed classes include:
• Beta-blockers: Propranolol and timolol are FDA-approved (exact mechanism in migraine is unknown/postulated; caution/contraindicated in asthma, low blood pressure, bradycardia, exercise intolerance).
• Antidepressants: Amitriptyline and nortriptyline are used at doses much lower than depression starting doses.
• Anti-seizure drugs: Topiramate (Topamax) and valproic acid (Depakote) are FDA-approved, acting to modulate ion channels, enhance GABA, and suppress glutamate (caution in women of reproductive potential due to teratogenicity).
• Calcium channel blockers: Less data exists for migraine prevention, but verapamil is a mainstay for cluster headache prevention, sometimes requiring >1,000 mg daily co-managed with cardiology and EKG monitoring.
• Botox (OnabotulinumtoxinA): Discovered serendipitously by California plastic surgeon Bill Binder. Counterintuitively, Botox does not work well for tension-type headache; it is FDA-approved specifically for chronic migraine ($\ge$15 days/month). Administered quarterly via the PREEMPT protocol (forehead, temples, back of head, neck, shoulders), it blocks SNARE/SNAP proteins and CGRP release rather than working via muscle relaxation. Insurers usually mandate failing 2 to 3 conventional preventives first.
• CGRP Antagonists, Triptans, & Medical Tourism: Serotonin was discovered in blood in the 1940s and found to drop during migraine attacks and rise in recovery, leading in the 1990s to sumatriptan (Imitrex) and 6 other triptans targeting $5\text{-HT}_{1\text{B}/1\text{D}}$ receptors. More recently, therapies targeting calcitonin gene-related peptide (CGRP) have transformed care:
• CGRP Monoclonal Antibodies (mAbs): Three are monthly/28-day self-injectables (~28-day half-life) and one is a quarterly IV infusion. They work in up to 60% of patients (taking 1–4 months for onset). Small-molecule gepants have shorter half-lives: atogepant (Qulipta) is for prevention; rimegepant (Nurtec) is for both acute and preventive use; ubrogepant (Ubrelvy) and zavegepant (Zavzpret nasal spray) are for acute use. Grosberg notes there are no large head-to-head trials comparing CGRP mAbs. Because U.S. drug costs are so high, Attia notes a patient flew first-class to Europe and stayed at the Four Seasons every three months to buy insulin and still saved money—and Grosberg confirms his headache patients do the exact same thing for migraine medications.
• Neuromodulation & Cannabinoids: Four external neuromodulation devices are FDA-cleared (with no head-to-head trials comparing them, and aside from one device studied for acute use, they are not formally studied in pregnancy though presumed safe): (1) a supraorbital trigeminal nerve stimulator (forehead), (2) a non-invasive vagus nerve stimulator (rented/leased monthly), (3) a remote electrical neuromodulation armband (Nerivio; app-controlled for acute and preventive use), and (4) a combined supraorbital and occipital nerve stimulator. Regarding cannabinoids/THC, Grosberg's outpatient survey found ~1/3 (33%) of headache patients use them, and one single-formulation acute RCT exists, but he cautions it is "next to impossible" to draw firm conclusions due to unstandardized formulations/routes, drug-drug interactions, and confounding indirect effects on sleep and anxiety.

Quotes

• At 0:01:03 - "Surprisingly, in medical school, maybe medical students and residents get a few hours across entire medical school of lectures." - Explaining why headache disorders are frequently underdiagnosed and undertreated across general medical practice.
• At 0:07:33 - "The differential diagnosis, the list of things is probably one of the most extensive in all of medicine, with over 300 different types and causes of headache." - Highlighting the complexity of headache classification in the absence of diagnostic blood or imaging biomarkers.
• At 0:10:27 - "Tension-type headache is the most common headache that people experience. Migraine is the leading reason why people seek care, either in their primary care office, with somebody like myself, or in an emergency room." - Distinguishing between population prevalence and clinical severity/healthcare utilization.
• At 0:11:51 - "Pain is often one-sided, but up to 40% of people with migraine can have pain that affects both sides of the head or the face. Most people don't know that." - Debunking the common misconception that a bilateral headache cannot be a migraine.
• At 0:14:50 - "Allodynia is a phenomenon where somebody experiences an uncomfortable sensation to things that normally aren't uncomfortable. An example would be a woman pulling their hair back in a ponytail, brushing their hair, wearing a tight hat, wearing glasses that rest on the rim of the nose or the eyes." - Defining cutaneous allodynia as a clinical marker of central sensitization during a migraine attack.
• At 0:15:17 - "The reason why that's important is when people experience this allodynia, if they use certain migraine-specific treatments like triptans, but they wait too long, those treatments may be less effective." - Explaining the physiological window of opportunity for acute rescue medications.
• At 0:16:33 - "About a quarter to a third of people with migraine will experience an aura. An aura is a reversible neurologic symptom, so most people with migraine actually do not experience aura." - Clarifying that 67% to 75% of migraine sufferers never experience visual or sensory auras.
• At 0:20:33 - "12%. So 1 billion worldwide, roughly 45 million people in the United States impacted by migraine." - Quantifying the global and national scale of migraine prevalence.
• At 0:23:14 - "And it disproportionately affects women three times more often than men." - Highlighting the major sex disparity in migraine epidemiology.
• At 0:24:50 - "Episodic migraine is where people have less than 15 days of migraine per month. Chronic migraine is where people experience 15 or more days of headache per month." - Defining the clinical threshold between episodic and chronic migraine.
• At 0:28:51 - "It's the faster rate of estrogen decline in that late luteal phase that is unique in women who experience migraine." - Detailing newer endocrine research on why drops in estrogen trigger perimenstrual migraine attacks.
• At 0:35:02 - "Triggers are not the cause of the headache. Triggers are factors that will elicit a headache in somebody who's biologically predisposed." - Shifting perspective from blaming external triggers to understanding underlying genetic and neurological predisposition.
• At 0:36:46 - "A headache diary is probably the most important thing that your listeners can do for not only themselves, because it really empowers patients, but for a clinician like me to understand because the patterns may be different from person to person." - Identifying the single most actionable diagnostic tool for patients and clinicians.
• At 0:42:16 - "Often people think that they have, quote, a sinus headache, but there's no such thing as a sinus headache. There is acute rhinosinusitis, there's chronic rhinosinusitis." - Explaining how trigeminal-autonomic symptoms during migraine masquerade as sinus disease.
• At 0:47:34 - "I have a woman patient who's likened it to giving birth to 100 babies at the same time without an epidural. I mean, that's the exquisite nature of the pain." - Conveying the extreme severity of cluster headache pain.
• At 0:49:34 - "And about 90% of people with cluster headache can experience a sense of restlessness with the attacks where they can't sit still. They need to move about. That's in contrast to migraine where the vast majority prefer to be still or lie down in a dark, quiet room." - Providing a clear behavioral differentiator between cluster headache and migraine during an acute attack.
• At 0:59:33 - "So people who are morbidly obese are at five times higher risk for more frequent migraine." - Connecting metabolic health and BMI $\ge$35 to the risk of migraine chronification.
• At 1:15:14 - "40% of people may be eligible based on indications for migraine prevention, but only like 16 or 17% are actually receiving preventive therapy." - Pointing out the massive treatment gap in preventive migraine care.
• At 1:34:34 - "If somebody doesn't respond to one of the treatments within the class, that does not dictate that they're not going to respond to another treatment in the class." - Advising clinicians and patients not to abandon the entire CGRP monoclonal antibody class if the first agent fails.
• At 1:44:18 - "The two largest culprits for the possibility of medication overuse are opiates and barbiturate-containing combination analgesics, like Fioricet or Fiorinal, which is even banned in some countries in the world." - Warning against specific acute medications that rapidly drive medication overuse headache.

Takeaways

• Maintain a monthly-view paper headache diary for 1 to 3 months: Before your medical appointment, track attack onset, duration, severity, sleep/wake times, meals, caffeine/alcohol intake, and menstrual cycles on a single monthly page so you and your doctor can visually spot multi-factor patterns.
• Take acute migraine medications (especially triptans) early, before allodynia sets in: Rescue medications lose efficacy once central sensitization (scalp/skin tenderness to normal touch, ponytails, or glasses) develops ~30 to 60 minutes into an attack; learn to recognize your premonitory/prodromal symptoms (yawning, neck stiffness, food cravings) to treat early.
• Limit acute pain medication use to fewer than 2 days per week: Using acute rescue analgesics $\ge$2 days per week regularly over an extended period can induce medication overuse headache and chronification; strictly avoid opioids and barbiturate-containing analgesics (Fioricet, Fiorinal), which carry the highest risk even when used just a handful of times per month.
• Match the acute delivery route to the speed of the attack: For cluster headaches (which peak in 5–15 minutes), rapid-onset waking migraines, or attacks with severe nausea/vomiting, bypass oral tablets (and sumatriptan liquid nasal spray, which has poor mucosal bioavailability) in favor of subcutaneous/IM sumatriptan (~9-minute median time to relief) or highly bioavailable nasal sprays like zolmitriptan (Zomig) or zavegepant (Zavzpret).
• Seek preventive therapy if you experience $\ge$5 headache days per month: Because having $\ge$5 headache days per month (or at least 1 migraine a week) significantly increases the risk of transitioning into chronic migraine, advocate for preventive therapy rather than relying solely on acute rescue drugs.
• Trial another CGRP antagonist if the first one fails: Give a CGRP monoclonal antibody 1 to 4 months to assess efficacy, and if it fails, try a different agent within the class—failing one CGRP mAb does not mean you will fail others.
• Reserve Botox specifically for chronic migraine ($\ge$15 days/month): Do not use Botox for tension-type headaches (where it is ineffective); for chronic migraine, ensure it is administered quarterly via the standardized PREEMPT protocol across the forehead, temples, back of the head, neck, and shoulders.
• Stabilize weekend sleep and caffeine schedules to prevent "letdown" migraines: Avoid sleeping in late on weekends and delaying your morning coffee by 2 to 3 hours; keep wake times, meal times, and caffeine intake consistent seven days a week.
• Address modifiable metabolic, sleep, and mood risk factors: To prevent episodic migraines from becoming chronic, actively treat sleep apnea and insomnia, manage depression and anxiety, address attack-related nausea, and pursue weight loss if overweight or obese (as BMI 30–35 doubles and BMI $\ge$35 quintuples the risk of frequent migraines).
• Re-evaluate "sinus headaches" before undergoing sinus or dental procedures: If you experience recurrent facial pressure, nasal congestion, or tearing alongside headaches, consult a neurologist or headache specialist to rule out migraine or cluster headache before consenting to sinus surgery or tooth extractions.
• Differentiate visual aura from TIA/stroke by timing and symptom quality: If visual disturbances evolve gradually over 5 to 60 minutes with positive phenomena (zigzags, shimmering lights), it points toward migraine aura; if visual loss is negative (darkness/blindness) and maximal at the exact moment of onset, seek immediate emergency care for a potential TIA or stroke.
• Seek immediate medical evaluation for "red flag" secondary headache symptoms: Go to the ER or seek urgent workup for any thunderclap headache (peaking within seconds to minutes), new headache onset after age 50 (to rule out temporal arteritis, which can hurt anywhere on the head/face), positional headache worsening upon standing or in the second half of the day with interscapular pain (potential CSF leak), new pattern changes, or headaches accompanied by fever, rash, inability to flex chin to chest, unintended weight loss, pregnancy, immunosuppression, or focal neurological deficits.